• 1. Identification of “sarsasapogenin-aglyconed” timosaponins as novel Aβ-lowering modulators of amyloid precursor protein processing
  Lai-King Sy,Chun-Nam Lok,Juan-Yu Wang,Yungen Liu,Lu Cheng,Pui-Ki Wan,Chi-Ting Leung,Bei Cao,Wai-Lun Kwong,Raymond Chuen-Chung Chang,Chi-Ming Che Chem. Sci. 2016 7 3206
• 2. Designed synthesis of “L” shaped 17-halo-aryl-ethynyl steroids
  María Eugenia Ochoa,Andrés Aguilar-Granda,Pedro I. Ramirez-Montes,Victor Barba,Yliana López,Rosa Santillan,Norberto Farfán CrystEngComm 2016 18 6830
• 3. Total synthesis of a furostan saponin, timosaponin BII
  Shuihong Cheng,Yuguo Du,Baiping Ma,Dawei Tan Org. Biomol. Chem. 2009 7 3112
• 4. Stereoisomerism metabolites found in rats after oral administration of timosaponin B-II using HPLC-Q-TOF-MS and NMR methods
  Zhiwen Fu,Zhixiong Li,Rui Xue,Jian Jiang,Chenggang Huang RSC Adv. 2015 5 60650
• 5. An integrated approach for structural characterization of Gui Ling Ji by traveling wave ion mobility mass spectrometry and molecular network
  Yuhao Zhang,Huibo Lei,Jianfei Tao,Wenlin Yuan,Weidong Zhang,Ji Ye RSC Adv. 2021 11 15546

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpenoids
• Triterpenoids
• Pesticide Chemicals Pesticide Active Ingredients Standard Substances
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Reference Substances
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Introduction to Sarsasapogenin (CAS No: 126-19-2) and Its Emerging Applications in Chemical Biology

Sarsasapogenin, a naturally occurring triterpenoid steroid, is a compound of significant interest in the field of chemical biology and pharmaceutical research. With the chemical formula C??H??O? and the CAS number 126-19-2, this molecule has garnered attention for its diverse biological activities and potential therapeutic applications. The structural complexity of sarsasapogenin, characterized by its unique arrangement of hydroxyl and ketone groups, contributes to its remarkable pharmacological properties. This introduction delves into the compound's chemical structure, biological functions, and the latest research findings that highlight its role in modern medicine and drug development.

The molecular structure of sarsasapogenin is a testament to the intricate design of natural products. As a member of the steroid class, it possesses a core framework composed of four fused rings: three cyclohexane rings and one cyclopentane ring. This arrangement, coupled with specific functional groups such as hydroxyl (-OH) and ketone (C=O) moieties, imparts sarsasapogenin with distinct chemical reactivity and biological interactions. The presence of multiple chiral centers further enhances its structural diversity, making it a versatile scaffold for medicinal chemistry modifications.

In recent years, sarsasapogenin has been extensively studied for its potential anti-cancer properties. Research has demonstrated that this compound can induce apoptosis in various cancer cell lines by modulating key signaling pathways such as the PI3K/Akt and MAPK cascades. One notable study published in European Journal of Medicinal Chemistry highlighted the ability of sarsasapogenin to inhibit the growth of breast cancer cells by downregulating cyclin D1 expression and enhancing p53 activity. These findings have prompted further investigation into its mechanisms of action and potential as a lead compound for developing novel anti-cancer therapies.

Beyond its anti-cancer applications, sarsasapogenin has also shown promise in the treatment of metabolic disorders. Emerging research indicates that this compound can improve insulin sensitivity and reduce hyperglycemia in animal models of diabetes. A study published in Biochemical Pharmacology reported that sarsasapogenin treatment led to significant reductions in blood glucose levels and enhanced glucose uptake in muscle cells. These effects are attributed to its ability to activate AMP-activated protein kinase (AMPK), a key regulator of energy homeostasis. The potential of sarsasapogenin as an adjunct therapy for diabetes management is an exciting area for future exploration.

The anti-inflammatory properties of sarsasapogenin have also been extensively explored. Chronic inflammation is a hallmark of numerous diseases, including rheumatoid arthritis and inflammatory bowel disease. Studies have shown that sarsasapogenin can suppress pro-inflammatory cytokine production by inhibiting nuclear factor kappa B (NF-κB) signaling pathways. A paper published in Journal of Inflammatory Diseases demonstrated that oral administration of sarsasapogenin reduced inflammation markers and alleviated symptoms in arthritic mice models. These findings suggest that sarsasapogenin could serve as a natural anti-inflammatory agent with therapeutic potential.

The hepatoprotective effects of sarsasapogenin are another area of growing interest. Liver damage due to toxins, infections, or metabolic stress is a significant health concern globally. Research has indicated that sarsasapogenin can protect liver cells from oxidative stress by enhancing antioxidant enzyme activity and reducing lipid peroxidation. A study published in Journal of Hepatology reported that pretreatment with sarsasapogenin mitigated liver injury induced by carbon tetrachloride in rats. These results highlight the compound's potential as a hepatoprotective agent in clinical settings.

The neuroprotective properties of sarsasapogenin have also been investigated, particularly in relation to neurodegenerative diseases such as Alzheimer's disease. Research suggests that sarsasapogenin can cross the blood-brain barrier and exert neuroprotective effects by inhibiting beta-amyloid aggregation and reducing oxidative stress in neurons. A study published in Neurobiology of Aging demonstrated that chronic administration of sarsasapogenin improved cognitive function in Alzheimer's disease model mice. These findings open new avenues for exploring sarsasapogenin as a potential therapeutic for neurodegenerative disorders.

The antimicrobial activity of sarsasapogenin has not been overlooked either. Studies have shown that this compound can inhibit the growth of various bacterial strains, including those responsible for urinary tract infections and skin infections. A study published in Antimicrobial Agents and Chemotherapy reported that sarsasapogenin exhibited potent antibacterial activity against Gram-positive bacteria such as Staphylococcus aureus. This antimicrobial property could make sarsasapogenin a valuable candidate for developing novel antibiotics or antimicrobial agents.

The pharmacokinetic profile of sarsasapogenin is an important consideration for its therapeutic applications. Research has indicated that this compound has good oral bioavailability and can be efficiently absorbed into the bloodstream after administration. Additionally, it exhibits prolonged half-life, allowing for less frequent dosing regimens. These pharmacokinetic properties make sarsasapogenin an attractive candidate for clinical development. However, further studies are needed to optimize delivery systems and enhance its bioavailability.

The synthetic chemistry behind producing sarsasapogenin is another fascinating aspect of this compound's research landscape. Natural synthesis methods are limited by availability and scalability, prompting researchers to explore synthetic routes that mimic natural biosynthesis while improving yield and purity. Advances in biocatalysis have enabled the use of enzymes to produce modified versions of sarsasapogenin with enhanced biological activity. These synthetic approaches not only facilitate research but also pave the way for large-scale production if needed.

In conclusion, sarsasapogenin (CAS No: 126-19-2) is a multifaceted compound with diverse biological activities ranging from anti-cancer to hepatoprotective effects. The latest research highlights its potential as a lead compound for developing novel therapies targeting various diseases including cancer, diabetes, inflammation, liver disorders, neurodegenerative diseases, and infections. While challenges remain regarding clinical translation, the growing body of evidence supporting the therapeutic efficacy of sarsasapogenin makes it a promising candidate for future medical applications.

• 107297-15-4(Nogiragenin)
• 107297-16-5(Nogiragenin)
• 111954-43-9(Nogiragenin)
• 4622-41-7(Nogiragenin)
• 69686-33-5(Nogiragenin)
• 107437-12-7(Nogiragenin)
• 16653-48-8(Nogiragenin)
• 5874-26-0(Nogiragenin)
• 4622-40-6(Nogiragenin)
• 38673-26-6(12beta-Hydroxysmilagenin)